 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | sipavibart (AZD3152) / AstraZeneca
Journal: AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. (Pubmed Central) - Jun 26, 2024
P2/3
Observed serum concentrations of AZD3152 through day 91 were similar to those observed with cilgavimab and consistent with predictions for AZD7442, a SARS-CoV-2-neutralizing antibody combination of cilgavimab and tixagevimab, in a population pharmacokinetic model. On the basis of its pharmacokinetic characteristics, AZD3152 is predicted to provide durable protection against symptomatic coronavirus disease 2019 caused by susceptible SARS-CoV-2 variants, such as JN.1, in humans.
- |||| Kavigale (sipavibart) / AstraZeneca, AZD5156 / AstraZeneca
Trial primary completion date: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (clinicaltrials.gov) - Jun 25, 2024
P2/3, N=3882, Active, not recruiting, Sponsor: AstraZeneca
On the basis of its pharmacokinetic characteristics, AZD3152 is predicted to provide durable protection against symptomatic coronavirus disease 2019 caused by susceptible SARS-CoV-2 variants, such as JN.1, in humans. Trial primary completion date: Sep 2023 --> Mar 2024
- ||||| Kavigale (sipavibart) / AstraZeneca, AZD5156 / AstraZeneca
Enrollment closed: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (clinicaltrials.gov) - Dec 18, 2023
P2/3, N=4038, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Sep 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- || Kavigale (sipavibart) / AstraZeneca, AZD5156 / AstraZeneca
Phase classification: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (clinicaltrials.gov) - Jul 3, 2023
P2/3, N=3706, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Phase classification: P3 --> P2/3
- Trial in progress: a phase I/III, randomised, modified double-blind, placebo- and active-controlled pre-exposure prophylaxis study of the SARS-CoV-2 (C / 06) - Apr 2, 2023 - Abstract #ECCMID2023ECCMID_5799;
- The SARS-CoV-2 monoclonal antibody AZD3152 potently neutralises historical and currently circulating variants (B / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_4766;
- |||||| Kavigale (sipavibart) / AstraZeneca, AZD5156 / AstraZeneca
Enrollment open, Enrollment change: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (clinicaltrials.gov) - Jan 13, 2023
P3, N=3256, Recruiting, Sponsor: AstraZeneca
Phase classification: P3 --> P2/3 Not yet recruiting --> Recruiting | N=1244 --> 3256
- |||||||||| Kavigale (sipavibart) / AstraZeneca, AZD5156 / AstraZeneca
New P3 trial: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (clinicaltrials.gov) - Dec 13, 2022
P3, N=1244, Not yet recruiting, Sponsor: AstraZeneca